Therefore, CD103 might be targeted for enhancing tumor immunity of CD8+T cells, and the infiltration of CD103+CD8+T cells in the liver TME might be considered as a biomarker to predict a better prognosis of the patients. Here, CD8A is linked to neoplasm.